Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — H1 2025 Earnings Presentation
26 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, September 2025
Slide 1: Interim Results Presentation
2025 Interim Results Presentation September 2025
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd., and no part of it shall form the
Slide 3: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 3
Slide 4: Key Business Highlights
Key Business Highlights Net loss 115mn Narrowed 59% YoY Overseas market sales: 176mn 150+orders ~90 ~60 7 Sales (RMB) FCF 135mn 103mn, +189% YoY +77% YoY 100+installed Toumai SkyWalker R-ONE Improved 43% YoY accumulatively for our product portfolio 1st 30+ globally approved remote new overseas order
Slide 5: Revenue Strides Ignited by Robust Global Market Momentum
Business Highlights Revenue Strides Ignited by Robust Global Market Momentum No.1 among domestic brands in terms of orders and (RMB mn) Toumai® installation base ➔ Accumulated ~90 units of orders received globally, covering 4 major continents - Europe, Asia, Africa and Asia Pacific Latin America (ot
Slide 6: Well-established and Widely-recognized Global Market Presence
Business Highlights Well-established and Widely-recognized Global Market Presence SRS2025: Highly recognized by global KOLs Russia Canada UK Netherland Belarus Belgium France Switzerland Serbia Bulgaria Uzbekistan EU US Turkey Italy China Japan Morocco Jordan Saudi UAE Arabia India Taiwan Philippine
Slide 7: Case studies
Business Highlights Demonstration of Leading Edge and Clinical Competency through Large-scale surgeries Surgical procedures Case studies Toumai® Maintained No.1 in terms of clinical operations among domestic brands Completed 12,000+ clinical surgeries up to date SkyWalkerTM Shanghai Pulmonary Hospit
Slide 8: World's 1st Approval – Ushering the Surgical Robot Industry into the Remote Era
Business Highlights World’s 1st Approval – Ushering the Surgical Robot Industry into the Remote Era April 2025 Dec 2024 & July 2025 Ruijin Hospital - A five-location remote surgery conducted for patients in Sanming World’s 1st satellite-based robotic (Fujian), Diqing (Yunnan), Ruijin (Jiangxi), tele
Slide 9: Multiple Flagship Products Gained Global Market Access
Business Highlights Multiple Flagship Products Gained Global Market Access Toumai® Toumai® Single-port Toumai® Remote SkyWalkerTM Obtained 10+ new registration Approved by NMPA in Feb 2025 Obtained NMPA approval in April 2025 Obtained CE mark for THA approvals in 1H25 Application Approved by MOHAP (
Slide 10: Improved Operational Effectiveness on Stringent Cost-optimization Strategies
Business Highlights Improved Operational Effectiveness on Stringent Cost-optimization Strategies Optimizing Net Loss Free Cash Outflow Gross profit Operational Narrowed Decreased Efficiency (RMB million) (RMB million) (RMB million) (RMB million) R&D S&M Admin 10.7% 42.2% 15.9% 486.4% 52.1% 1,146.3 1
Slide 11: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 11
Slide 12: Comprehensive product offering covering all major and fast-growing surgical specialties
Product Pipeline Update Comprehensive product offering covering all 5 major and fast-growing surgical specialties Medical Device Surgical Product Clinical Trial/ Specialty Product Indicated Application Classification Design Development Design Validation Clinical Evaluation Registration Application I
Slide 13: Flagship product – Toumai Laparoscopic Surgical Robot
Product Pipeline Update Flagship product– Toumai® Laparoscopic Surgical Robot Multiple generations of Domestic Leader with premium quality demonstrated in large-scale clinical validation Toumai® clinical progress • Maintained leading position, #1 market share among domestic brands with ramped up win
Slide 14: Flagship product – SkyWalker Orthopedic Surgical Robot
Product Pipeline Update Flagship product – SkyWalkerTM Orthopedic Surgical Robot The 1st domestic surgical robot to expand into global market 2022 2023 2024 2025 China (NMPA) India China (NMPA, THA) Europe (CE, THA) US (FDA) Japan Brazil Thailand Europe (CE) UK Australia More to expect… Canada Conti
Slide 15: Natural Orifice Surgical Robot
Product Pipeline Update Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Product Surgery application ◼ Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human bod
Slide 16: R-ONE Vascular Interventional Robot System
Product Pipeline Update R-ONE® Vascular Interventional Robot System Designed to operate with precision and NMPA approval perform specific movements CE mark Facilitate and enhance the interventional procedures performed on the patient Clinical Performance Strong Commercialization Unique Synergy & Lea
Slide 17: Mona Lisa Robotic Transperineal Prostate Biopsy System
Product Pipeline Update Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA Approval Real-time ultrasound images displayed on the monitor FDA Approval during the biopsy procedure CE Marking TGA Approval The surgeon manually inserts the needle into the prostate to collect the biopsy cores HAS
Slide 18: Strong industrial operation capabilities for surgical robots
Product Pipeline Update Strong industrial operation capabilities for surgical robots g pply chain eadin R&D 1,352 u L S Multilayered supply chain system applications In-house designed components 550 Scalable production of Toumai®, SkyWalkerTM and consumables granted (369 in China; 181 overseas) Annu
Slide 19: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 19
Slide 20: Consolidated Financial Performance
Financial Review Consolidated Financial Performance REVENUE TOTAL NET LOSS FREE CASH FLOW Total revenue reached 175.7m with a growth rate of 77%, Total net loss decreased from 280.0m for the six months The success of revenue growth, costs reduction and mainly attributable to the rapid commercial exp
Slide 21: Operating Expenses
Financial Review Operating Expenses R&D COST S&M EXPENSES ADMINISTRATIVE EXPENSES (RMB million) (RMB million) (RMB million) -72% 267% 27% -77% 47% 13% 46% 126.9 92.2 61% 311.7 80.4 93% 40% 164.1 77.6 88.6 46% 30.1 18.1 23A 1H 24A 1H 25A 1H 23A 1H 24A 1H 25A 1H 23A 1H 24A 1H 25A 1H % of Revenue R&D 8
Slide 22: In Closing
In Closing We delivered record revenue and robust momentum to drive continuous growth We enjoy large, global market opportunities Our comprehensive product pipeline enables technology integration, stimulates sales synergy, and provides integrated diagnostic and treatment solutions We are positioned
Slide 23: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 23
Slide 24: Appendix I - Consolidated Balance Sheet
Appendix I - Consolidated Balance Sheet Unit: RMB'000 30 Jun 2025 31 Dec 2024 Var. Unit: RMB'000 30 Jun 2025 31 Dec 2024 Var. Non-current assets CAPITAL AND RESERVES Property, plant and equipment 251,102 297,371 -16% Intangible assets 2,733 3,972 -31% Share capital 1,031,330 1,006,194 2% Goodwill 1,
Slide 25: Appendix II - Consolidated P&L
Appendix II - Consolidated P&L Unit: RMB'000 30 Jun 2025 30 Jun 2024 Var. Revenue 175,689 99,237 77% Cost of sales (104,183) (52,224) 99% Gross profit 71,506 47,013 52% Other net income 519 5,298 -90% Selling and marketing expenses (80,411) (92,223) -13% Administrative expenses (18,055) (30,072) -40
Slide 26: Thank You
4) MEDBOT o) rk BUN ES A.
Shanghai MicroPort MedBot (Group) — H1 2025 Earnings Presentation on 6ix